File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Hepatitis C virus infection in patients on renal replacement therapy

TitleHepatitis C virus infection in patients on renal replacement therapy
Authors
KeywordsChronic Disease
Hepatitis/Diagnosis
Kidney Transplantation
Rna
Viral/Analysis
Issue Date2002
PublisherLippincott Williams & Wilkins Asia. The Journal's web site is located at http://www.hkjn.org/
Citation
Hong Kong Journal Of Nephrology, 2002, v. 4 n. 1, p. 3-12 How to Cite?
AbstractHepatitis C virus infection is a frequent clinical problem in patients on dialysis and renal transplant recipients. The local prevalence rates of hepatitis C virus infection in patients on peritoneal dialysis, hemodialysis, or after kidney transplantation are 2%, 9%, and 6%, respectively. Conventional diagnosis of hepatitis C virus infection is by anti-hepatitis C virus immunoassays. However, up to 10% of immunosuppressed patients may be negative for anti-hepatitis C virus but positive for hepatitis C virus RNA. Repeated blood transfusions and a long duration of dialysis are major risk factors for hepatitis C virus infection among patients with renal failure. Although the risk of acquiring hepatitis C virus infection through transfusions has decreased considerably with the advent of screening tests for anti-hepatitis C virus, precautionary measures should be instituted rigorously at renal units to prevent nosocomial transmission. Hepatitis C virus infection in dialysis patients often assumes a relatively mild course. In contrast, renal allograft recipients can develop potentially life-threatening exacerbations, as exemplified by fibrosing cholestatic hepatitis. Liver disease of variable severity can be observed in about two thirds of hepatitis C virus-positive renal allograft recipients. In the majority of patients, however, the adverse effect of hepatitis C virus infection on survival may not be evident in the first decade after renal transplantation. Hepatitis C virus-positive patients with renal failure should not be excluded from kidney transplantation, but should be assessed individually with regard to the severity of liver disease before transplantation. Dialysis patients with hepatitis C virus infection, especially those with a potential for kidney transplantation, should be considered for treatment with interferon, because the risk of interferon in inducing renal allograft dysfunction is too high to justify its routine use in renal allograft recipients.
Persistent Identifierhttp://hdl.handle.net/10722/162607
ISSN
2015 SCImago Journal Rankings: 0.166
References

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_US
dc.date.accessioned2012-09-05T05:21:36Z-
dc.date.available2012-09-05T05:21:36Z-
dc.date.issued2002en_US
dc.identifier.citationHong Kong Journal Of Nephrology, 2002, v. 4 n. 1, p. 3-12en_US
dc.identifier.issn1561-5413en_US
dc.identifier.urihttp://hdl.handle.net/10722/162607-
dc.description.abstractHepatitis C virus infection is a frequent clinical problem in patients on dialysis and renal transplant recipients. The local prevalence rates of hepatitis C virus infection in patients on peritoneal dialysis, hemodialysis, or after kidney transplantation are 2%, 9%, and 6%, respectively. Conventional diagnosis of hepatitis C virus infection is by anti-hepatitis C virus immunoassays. However, up to 10% of immunosuppressed patients may be negative for anti-hepatitis C virus but positive for hepatitis C virus RNA. Repeated blood transfusions and a long duration of dialysis are major risk factors for hepatitis C virus infection among patients with renal failure. Although the risk of acquiring hepatitis C virus infection through transfusions has decreased considerably with the advent of screening tests for anti-hepatitis C virus, precautionary measures should be instituted rigorously at renal units to prevent nosocomial transmission. Hepatitis C virus infection in dialysis patients often assumes a relatively mild course. In contrast, renal allograft recipients can develop potentially life-threatening exacerbations, as exemplified by fibrosing cholestatic hepatitis. Liver disease of variable severity can be observed in about two thirds of hepatitis C virus-positive renal allograft recipients. In the majority of patients, however, the adverse effect of hepatitis C virus infection on survival may not be evident in the first decade after renal transplantation. Hepatitis C virus-positive patients with renal failure should not be excluded from kidney transplantation, but should be assessed individually with regard to the severity of liver disease before transplantation. Dialysis patients with hepatitis C virus infection, especially those with a potential for kidney transplantation, should be considered for treatment with interferon, because the risk of interferon in inducing renal allograft dysfunction is too high to justify its routine use in renal allograft recipients.en_US
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins Asia. The Journal's web site is located at http://www.hkjn.org/en_US
dc.relation.ispartofHong Kong Journal of Nephrologyen_US
dc.subjectChronic Diseaseen_US
dc.subjectHepatitis/Diagnosisen_US
dc.subjectKidney Transplantationen_US
dc.subjectRnaen_US
dc.subjectViral/Analysisen_US
dc.titleHepatitis C virus infection in patients on renal replacement therapyen_US
dc.typeArticleen_US
dc.identifier.emailChan, TM:dtmchan@hku.hken_US
dc.identifier.authorityChan, TM=rp00394en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.scopuseid_2-s2.0-0036372673en_US
dc.identifier.hkuros79049-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036372673&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume4en_US
dc.identifier.issue1en_US
dc.identifier.spage3en_US
dc.identifier.epage12en_US
dc.publisher.placeHong Kongen_US
dc.identifier.scopusauthoridChan, TM=7402687700en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats